Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ed Schuuring

Showing results (161-170 of 210) with videos related to

Pageof 21
Sort By:
Genes, Chromosomes & Cancer|September 23, 2015
Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinomaMartijn J A M Clausen, Lieuwe J Melchers, Mirjam F Mastik, et al.
BMC Medicine|June 24, 2017
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancerTushar Tomar, Nicolette G Alkema, Leroy Schreuder, et al.
Targeted Oncology|June 5, 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose OsimertinibFenneke Zwierenga, M Benthe Muntinghe-Wagenaar, Pim Rozendal, et al.
Plos One|August 8, 2013
Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcomeGerald S M A Kerner, Ed Schuuring, Johanna Sietsma, et al.
International Journal of Molecular Sciences|September 9, 2023
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer PatientsPaul van der Leest, Melanie Janning, Naomi Rifaela, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancerMaartje G Noordhuis, Jasper J H Eijsink, Klaske A Ten Hoor, et al.
JCO Precision Oncology|January 20, 2022
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational ProfilesBart Koopman, Anthonie J van der Wekken, Arja Ter Elst, et al.
Journal of Clinical Pathology|September 28, 2011
EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapyErik Thunnissen, Judith V M G Bovée, Hans Bruinsma, et al.
JCO Precision Oncology|January 7, 2022
Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsSabrina Weber, Paul van der Leest, Hylke C Donker, et al.
The Journal of Molecular Diagnostics : JMD|November 19, 2022
A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical PracticeAstrid Kramer, Ed Schuuring, Daan C L Vessies, et al.
Pageof 21

Showing results (161-170 of 210) with videos related to

Sort By:
Pageof 21
Genes, Chromosomes & Cancer|September 23, 2015
Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinomaMartijn J A M Clausen, Lieuwe J Melchers, Mirjam F Mastik, et al.
BMC Medicine|June 24, 2017
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancerTushar Tomar, Nicolette G Alkema, Leroy Schreuder, et al.
Targeted Oncology|June 5, 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose OsimertinibFenneke Zwierenga, M Benthe Muntinghe-Wagenaar, Pim Rozendal, et al.
Plos One|August 8, 2013
Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcomeGerald S M A Kerner, Ed Schuuring, Johanna Sietsma, et al.
International Journal of Molecular Sciences|September 9, 2023
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer PatientsPaul van der Leest, Melanie Janning, Naomi Rifaela, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancerMaartje G Noordhuis, Jasper J H Eijsink, Klaske A Ten Hoor, et al.
JCO Precision Oncology|January 20, 2022
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational ProfilesBart Koopman, Anthonie J van der Wekken, Arja Ter Elst, et al.
Journal of Clinical Pathology|September 28, 2011
EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapyErik Thunnissen, Judith V M G Bovée, Hans Bruinsma, et al.
JCO Precision Oncology|January 7, 2022
Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsSabrina Weber, Paul van der Leest, Hylke C Donker, et al.
The Journal of Molecular Diagnostics : JMD|November 19, 2022
A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical PracticeAstrid Kramer, Ed Schuuring, Daan C L Vessies, et al.
Pageof 21